Edition:
United States

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

9.89USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$9.89
Open
--
Day's High
--
Day's Low
--
Volume
25
Avg. Vol
69,296
52-wk High
$24.00
52-wk Low
$8.70

Latest Key Developments (Source: Significant Developments)

Selecta Biosciences announces Q3 loss per share $0.66
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces third quarter 2017 financial results and provides corporate update.Q3 revenue $100,000 versus $1.0 million.Q3 revenue view $383,000 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.66.Selecta -‍ Cash, cash equivalents, short-term deposits, investments & restricted cash sufficient to fund expenditure requirements into mid-2019​.  Full Article

Selecta Biosciences names John Leaman chief financial officer
Thursday, 26 Oct 2017 08:00am EDT 

Oct 26 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences announces important additions to senior leadership team.Selecta Biosciences Inc - ‍Appointment of John Leaman as company's new chief financial officer and head of corporate strategy​.  Full Article

Selecta Biosciences files for mixed shelf of up to $‍​200 mln - SEC Filing
Friday, 11 Aug 2017 07:55am EDT 

Aug 11 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences Inc files for mixed shelf of up to $‍​200 million - SEC Filing.  Full Article

Selecta Biosciences Q2 loss per share $0.85
Friday, 11 Aug 2017 07:00am EDT 

Aug 11 (Reuters) - Selecta Biosciences Inc :Selecta biosciences announces second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.85.Q2 revenue $100,000 versus $2.0 million.Q2 revenue view $557,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.90 -- Thomson Reuters I/B/E/S.Selecta biosciences - expects cash, cash equivalentswill be sufficient to fund co's operating expenses and capital expenditure requirements into 2019.  Full Article

Selecta Biosciences files for offering of 3.2 mln shares by selling stockholders
Thursday, 13 Jul 2017 06:18am EDT 

July 13 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences files shelf prospectus relating to proposed offering and resale of 3.2 million shares of common stock by selling stockholders - SEC filing.  Full Article

Vivo Capital VIII reports 5.1 pct passive stake in Selecta Biosciences
Friday, 30 Jun 2017 04:55pm EDT 

June 30 (Reuters) - Vivo Capital VIII Llc::Vivo Capital VIII Llc reports 5.1 percent passive stake in Selecta Biosciences Inc, as of June 26, 2017 - SEC filing.  Full Article

Selecta Biosciences reports $50 mln private placement
Monday, 26 Jun 2017 08:00am EDT 

June 26 (Reuters) - Selecta Biosciences Inc ::Selecta Biosciences announces $50 million private placement.Selecta Biosciences Inc - entered agreements to sell securities in private placement that is expected to result in proceeds to company of $50 million.Selecta Biosciences Inc - plans to use proceeds from financing primarily for ongoing clinical development of selecta's lead product candidate, sel-212.Selecta Biosciences-expects addition of proceeds to balance sheet will enable co to fund operating expenses,capital expenditure requirements into 2019.Selecta Biosciences Inc - certain new,existing institutional investors agreed to purchase aggregate of 2.75 million shares at a price of $16.00 per share.Selecta Biosciences Inc - additionally, a member of board agreed to purchase, for aggregate purchase price of about $6 million, shares and warrants.  Full Article

Selecta Bio provides data from mid-stage study testing gout drug
Thursday, 15 Jun 2017 07:30am EDT 

June 15 (Reuters) - Selecta Biosciences Inc :Selecta Biosciences reports data from ongoing phase 2 trial of lead candidate, sel-212, in development for chronic severe gout.Sel-212 generally well tolerated.Reduced rate of gout flares with sel-212.Selecta Biosciences - majority of patients in minimum effective dose group in study maintained sua control following three monthly injections of sel-212.Selecta Biosciences Inc - in relation to sel-212, there have been total of eight serious adverse events reported in trial through june 12, 2017.Selecta Biosciences - to initiate phase 3 program for sel-212 in 2018 following further dialogue with u.s. Food and drug administration.Selecta Biosciences Inc - one additional sae, cholecystitis, was determined to not be related to study drug.Selecta Biosciences Inc - all of saes related to sel-212 study were successfully treated and resolved without further issues.  Full Article

Selecta Biosciences notifies Spark Therapeutics about license agreement
Friday, 9 Jun 2017 05:37pm EDT 

June 9 (Reuters) - Spark Therapeutics Inc ::Selecta Biosciences-on june 5,notified Spark Therapeutics, license agreement would terminate as Spark had not made may 2017 license payment by may 31.  Full Article

Selecta Biosciences Q1 loss per share $0.82
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - Selecta Biosciences Inc ::Selecta Biosciences announces first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.82.Q1 revenue $100,000 versus $2.1 million.  Full Article

BRIEF-Selecta Biosciences announces Q3 loss per share $0.66

* Selecta Biosciences announces third quarter 2017 financial results and provides corporate update